GLP1R and rheumatoid arthritis: In this cohort study of 140 308 patients with type 2 diabetes, treatment with tirzepatide was associated with significantly lower hazards of all-cause mortality and major adverse cardiovascular and kidney events compared with GLP-1 RA.